DE602004031030D1 - Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten - Google Patents

Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten

Info

Publication number
DE602004031030D1
DE602004031030D1 DE602004031030T DE602004031030T DE602004031030D1 DE 602004031030 D1 DE602004031030 D1 DE 602004031030D1 DE 602004031030 T DE602004031030 T DE 602004031030T DE 602004031030 T DE602004031030 T DE 602004031030T DE 602004031030 D1 DE602004031030 D1 DE 602004031030D1
Authority
DE
Germany
Prior art keywords
heteroaryl
receptor agonists
glutamate receptor
imidazole derivatives
substituted imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031030T
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Porter
Eric Vieira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004031030D1 publication Critical patent/DE602004031030D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602004031030T 2003-06-12 2004-06-07 Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten Expired - Lifetime DE602004031030D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012290 2003-06-12
PCT/EP2004/006111 WO2004111040A1 (en) 2003-06-12 2004-06-07 Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
DE602004031030D1 true DE602004031030D1 (de) 2011-02-24

Family

ID=33495606

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031030T Expired - Lifetime DE602004031030D1 (de) 2003-06-12 2004-06-07 Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten

Country Status (24)

Country Link
US (1) US7241760B2 (de)
EP (1) EP1670784B1 (de)
JP (1) JP4395512B2 (de)
KR (1) KR100717914B1 (de)
CN (1) CN100462363C (de)
AR (1) AR044657A1 (de)
AT (1) ATE495168T1 (de)
AU (1) AU2004247368B2 (de)
BR (1) BRPI0411350A (de)
CA (1) CA2527587C (de)
CL (1) CL2004001430A1 (de)
CO (1) CO5660263A2 (de)
DE (1) DE602004031030D1 (de)
ES (1) ES2358512T3 (de)
HK (1) HK1093071A1 (de)
IL (1) IL172080A (de)
MX (1) MXPA05013233A (de)
MY (1) MY140206A (de)
NO (1) NO332175B1 (de)
NZ (1) NZ543638A (de)
RU (1) RU2327697C2 (de)
TW (1) TWI336700B (de)
WO (1) WO2004111040A1 (de)
ZA (1) ZA200509908B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
MX2007011483A (es) * 2005-03-23 2007-10-12 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de glutamato metabotropico 2.
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US9447099B2 (en) 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
CN114746408A (zh) * 2019-12-02 2022-07-12 豪夫迈·罗氏有限公司 炔基-(杂芳基)-甲酰胺hcn1抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354867A (en) * 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
ES2346513T3 (es) * 2000-07-24 2010-10-18 Krenitsky Pharmaceuticals, Inc. 5-alquinil pirimidinas sustituidas que tienen actividad neurotrofica.
DE10040683C2 (de) * 2000-08-19 2002-06-27 Hinderer & Muehlich Kg Verfahren zum Positionieren einer Patrize an einer Gegendruckwalze einer Prägestation
WO2002046166A1 (en) * 2000-12-04 2002-06-13 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists

Also Published As

Publication number Publication date
NO20055758D0 (no) 2005-12-05
MY140206A (en) 2009-11-30
ZA200509908B (en) 2006-11-29
CL2004001430A1 (es) 2005-05-06
KR100717914B1 (ko) 2007-05-11
WO2004111040A1 (en) 2004-12-23
MXPA05013233A (es) 2006-03-09
NZ543638A (en) 2008-05-30
JP2006527203A (ja) 2006-11-30
KR20060021886A (ko) 2006-03-08
CO5660263A2 (es) 2006-07-31
AR044657A1 (es) 2005-09-21
BRPI0411350A (pt) 2006-07-11
ES2358512T3 (es) 2011-05-11
CA2527587C (en) 2010-09-28
US7241760B2 (en) 2007-07-10
EP1670784A1 (de) 2006-06-21
ATE495168T1 (de) 2011-01-15
CN100462363C (zh) 2009-02-18
CN1802368A (zh) 2006-07-12
NO332175B1 (no) 2012-07-16
EP1670784B1 (de) 2011-01-12
RU2006100106A (ru) 2007-07-20
TWI336700B (en) 2011-02-01
US20040254179A1 (en) 2004-12-16
IL172080A (en) 2012-03-29
RU2327697C2 (ru) 2008-06-27
HK1093071A1 (en) 2007-02-23
NO20055758L (no) 2005-12-07
CA2527587A1 (en) 2004-12-23
TW200510331A (en) 2005-03-16
AU2004247368B2 (en) 2007-11-22
AU2004247368A1 (en) 2004-12-23
JP4395512B2 (ja) 2010-01-13

Similar Documents

Publication Publication Date Title
DE60320439D1 (de) Indolderivate als beta-2 agonisten
ATE504559T1 (de) Arylanilinderivate als agonisten des beta2- adrenergen rezeptors
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60317365D1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE513827T1 (de) Oxyindol-derivate als 5ht4-rezeptor-agonisten
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE435207T1 (de) Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten
DE602004009796D1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
DK1745009T3 (da) Heteroarylsubstituerede cyklohexyl-1,4-diamin-derivater
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE523505T1 (de) Imidazol-derivate als tafia-inhibitoren
ATE435225T1 (de) Oxadiazolonderivate als ppar-delta-agonisten
NO20055758D0 (no) Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
DK1725232T3 (da) (Indol-3-yl)-heterocykliske derivater som agonister for cannabinoid-CB1-receptoren
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
ATE325123T1 (de) Imidazoquinoline derivate als adenosine a3 rezeptor liganden
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten